Piper Jaffray Upgrades Akorn (AKRX) to Overweight

September 15, 2016 7:00 AM EDT
Get Alerts AKRX Hot Sheet
Price: $24.61 --0%

Rating Summary:
    13 Buy, 8 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 0
Trade AKRX Now!
Join SI Premium – FREE

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

(Updated - September 15, 2016 10:11 AM EDT)

Piper Jaffray upgraded Akorn (NASDAQ: AKRX) from Neutral to Overweight with a price target of $34. Analyst David Amsellem noted favorable/stable dynamics surrounding key products in the base generics business.

Amsellem explained, "Though there is still uncertainty over the longer-term trajectory and competitive dynamics surrounding injectable ephedrine (which accounted for 21% of 2Q16 sales), a closer look at overall volume trends across the AKRX commercial portfolio suggests to us that the base business is on sustainable footing. That dynamic along with a deep pipeline (85+ pending abbreviated NDA (aNDA) filings) makes it easier for us to envision at least modest earnings growth in 2017 even in the face of pressure on ephedrine, and with the impact of new approvals, accelerating EPS growth beyond 2017. This points to an attractive valuation in the context of a P/E of 12x our 2017 EPS estimate of $2.38 (and the strong balance sheet, with debt/EBITDA of 1.3x, doesn't hurt either)."

For an analyst ratings summary and ratings history on Akorn click here. For more ratings news on Akorn click here.

Shares of Akorn closed at $27.56 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View, Upgrades

Related Entities

Piper Jaffray, Earnings

Add Your Comment